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Results: The serum C (250.9*38.5 vs.1137.0~24.5mgldl PcO.05) and LDL-C(l70.7*42.2 
vs. 123&18.0mgldl.P<0.05) decreased significantly after A. However, no significant ele- 
vation of C and LDL-C was noted after withdrawal of A. The VCAM-1(592.01+208.31 
~~508.43~178.04 @ml) and the iSO(14.43i8.91 vslO.56+3.31 pgiml) were significantly 
decreased and the tPA( 8.73i3.82 vs. 11.33 * 4.50 @ml) was significantly elevated 
after A. Of note, the VCAM-1 and IS0 were significantly increased to 591.18 * 203.65ngl 
ml and 12.34 * 4.53 ng/ml respectively at day 2 after wthdrawal of A. The tPA decreased 
significantly to 9.98i3.67 nglml at day 3. 
Conclusion: After 12 wks of A, the positwe pleiotropic effects of statln are demonstrated 
simultaneously with lowering the serum C However, after withdrawal of A, these pleiotro- 
pit effects are significantly abrogated withln days and are independent on the elevation 
Of serum c. 
1156-154 Prevalence of Risk Factors for Coronary Disease in 
Myocardial Infarction in the Community 
Francisco Lopez-Jimenez Steven J. Jacobsen, Guy S. Reeder, Susan A. Weston, Jill M. 
Killian, Ryan Meverden, VBronique L. Roger, Mayo Clinic, Rochester, MN 
While reports suggest that the prevalence of cardiovascular risk factors (CV RF) in acute 
myocardial infarction (Ml) may be low. there is a paucity of data on the prevalence of 
modifiable CV RF among patients with Ml in a geographically defined populatton, and it is 
not known whether the prevalence is changing over time. 
OBJECTIVES: To determine the overall prevalence of CV RF among patients with Ml in 
the population and their change over time 
DESIGN: Population-based MI incidence cohort. 
METHODS: We analyzed the prevalence of major modlflabk CV RF including over- 
weight/obesity, history of smoking, diabetes mellitus, hypertension and hyperlipidemia; 
and non-modifiable CV RF including age?75 years, male sex or family history of coronary 
disease among all residents of Olmsted County, MN, hospitalized for a validated incident 
Ml between 1979 and 1998. Demographic and clinical characteristics were collected 
from community medical records. 
RESULTS: During the study period, 2,277 subjects had a Ml. Only 3.6% of patients did 
not have modifiable CV RF. When compared to patients with a Ml from 1979-83, patients 
who had the Ml from 1994-98 were more likely to be overweightiobese. 72% vs. 58%; or 
to have history of hypertension, 61% vs. 50%; or hyperlipidemia, 44% vs. 21%; and less 
likely to have history of smoking, 65% vs. 70%; or to be male, 55% vs. 61%, all with a 
PcO.05 including the four B-year groups. There was no difference in the prevalence of 
diabetes, famtly history of coronary disease or being >75 years old. In patients S65 years 
of age, those who had a Ml from 1994-98 were 72% more likely to be obese (EM1230 Kg/ 
m2) 43% vs. 25%; and either overweight or obese, 82% vs. 70%; and more likely to have 
diagnosis of hyperlipidemia. 47% vs. 29%; but less likely to have history of smoking, 79% 
vs. 89%. than patients who had the MI 15 years earlier. The prevalence of patients with 
24 mafor modifiable CV RF increased from 13% to 22% in the same period. 
CONCLUSIONS: Conversely to what has been reported in other senings, very few 
patients with incident MI in the community do not have any CV RF. The high prevalence 
and average number of modifiable CV RF and their trend in patients with Ml is underscor- 
ing the importance of secondary preventlon after Ml. 
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845-l The Influence of the Metabolic Syndrome on 24-Year 
Mortality Among Middle-Aged Men in the Multiple Risk 
Factor Intervention Trial (MRFIT) 
Jerome D. Cohen. Lynn E Eberly, Ronald Prineas, Gabriela Vasquez, MRFIT Research 
Group, Saint Louis University, St. Louis, MO, Uwersity of Minnesota. Minneapolis, MN 
Background: The Metabolic Syndrome (MS) has been recently defined and identified as 
an Important clustenng of risk factors for cardiovascular disease (CVD). We explored the 
long-term mortality of men with MS and with or without corxurrent untreated diabetes 
mellitus (DM). 
Methods: 12,617 men who participated in the MRFIT were classified according to base- 
line presence of MS and/or DM not on hypoglycemic agents. MS was defined as three or 
more of: body mass index 30+ kg/&, triglycerides 150+ mg/dL, high-density-lipoprotein 
cholesterol ~40 mg/dL. blood pressure 130+ / 85+ mm Hg, and fastmg glucose 1 10+ mgl 
dL. Untreated DM was defined as fasting glucose 126+ mg/dL and not on hypoglycemic 
agents. Proportional hazards regression models were fit for total and CVD mortality with 
adjustment for age, race, cigarette smoking, alcoholic drinks, total cholesterol. uric acid, 
and randomized treatment group (intervention: smoking cessation counseling, dietary 
counseling to lower cholesterol, and hypertension medication; control: usual care by per- 
sonal physician). 
Results: 4,735 men had MS only, 57 had DM only, and 355 had both; 42 men on 
hypcglycemlc agents ware excluded. There were 4,556 total and 2,221 CVD deaths war 
median follow-up of 24.4 years. Average blood pressure was reduced from 135191 mm 
Hg at baseline to 124/82 after 6 years; average cholesterol was reduced from 240 to 231 
mg/dL. Adjusted hazard ratios (HA) for CVD mortality relative to those with neither MS 
nor DM were 1.27 for those with MS only [p<O.OOOl], 1.37 for those with DM only 
[p=O.28], and 1.99 for those with both MS and DM [p-zO.OOOl]. Results were similar for 
total mortality with HAS of 1.15 [p<O.OOOl], 1.63 [p=O.Ol], and 1.68 [p<O.OOOl] respec- 
tively. 
Conclusions: The presence of MS with or without untreated DM was associated with a 
significantly increased risk in mortality compared to those with neither MS nor DM. Thus 
the treatment of MS and its individual components are an important part of the strategy 
for the prevention of CVD. 
10:45 a.m. 
845-2 Niacin Decreases Myocardial Infarction and Total 
Mortality in Patients With Metabolic Syndrome: Results 
From the Coronary Drug Project 
Paul L. Canner, Curl D. Furberg, Michael L. Terrin. Mark E. McGovern, Maryland Medical 
Research Institute, Baltimore, MD, Wake Forest University, Winston-Salem. NC 
Background: In the Coronary Drug Project (CDP), niacin decreased recurrent nonfatal 
myocardial Infarction (NFMI) by 28% at 6 years (study end) and total mortality by 11% at 
15 years (9 years post-trial). Since niacin may affect insulin sensitivity, and new national 
guidelines emphasize the importance of metabolic syndrome (MS), ws evaluated 
whether n&n’s effects on clinical outcomes were similar in patients with and without 
MS. We therefore analyzed results in that subgroup from CDP using National Cholesterol 
Education Program Adult Treatment Panel Ill criteria. 
Methods: We defined MS as at least 3 of: triglycerides $50 mgldL; blood pressure 
~130/>85 mmHg; fasting glucose 2110 but cl26 mg/dL; or body mass index >28 (as a 
substitute for waist circumference). High-density lipoprotein cholesterol (HDL-C) had 
been measured in a small number of patients (N=492), so a second analysis added HDL- 
C < 40 mg/dL as a cnterion for MS. Relative hazards (RH) and Z-values for homogeneity 
of treatment effect between subgroups were computed. 
Results: Results are shown below. The Z-values for ho&geneity indicate no significant 
difference in effect between patients with and without MS. For the subpopulation with 
HDL-C values, event rates overall were: NFMI 8.7% for niacin versus 15.2% for placebo 
(Z = -1.92. RH = 0.55); total mortality, 58.0% for niacin versus 66.1% for placebo (Z = - 
1.69, RH = 0.80). 
Conclusions: We conclude that in the CDP, niacin reduced NFMI and mortality in 
patients both with and without MS. 
Coronary Drug Project Results In Patents With or Without Metabolic Syndrome 
NFMI (6 years) Total Mortality (15 years) 
Analysis Not Including HDL-C 
+MS -MS +MS -MS 
N=563 N=3,343 N=563 N=3,343 
Niacin % 12.2 10.0 58.3 50.9 
Placebo % 16.0 14.0 61.7 57.4 
Relative Hazard 0.75 0.70 0.91 0.83 
Z(homogeneity) 
0.07 0.64 
Analysis including HDL-C 
+MS -MS +MS -MS 
N=124 N=366 N=l24 NC366 
Niacin % a.8 0.7 52.9 59.6 
Placebo % 25.6 11.7 64.4 66.7 
Relatwe Hazard 0.31 0.72 0.73 0.83 
2 (homogeneity) 
-1.74 -0.40 
1 I:00 a.m. 
845-3 The Metabolic Syndrome Is an Independent Predictor of 
Cardiac Events in WOSCOPS Males 
Gilbert J. L’ltalien, Ian Ford, James Shepherd, Bristol Myers-Squibb, Wallingford, CT, 
University of Glasgow, Glasgow, Unlted Kingdom 
Background: The Metabolic Syndrome (METS) is characterized by component condi- 
tions of dyslipldemia, hypertension, insulin resistance, and obesity. Although the syn- 
drome is recognized as a CHD risk equivalent by the ATPIII guidelines committee, there 
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is as yet no data providing the independent and quantitative effect of the syndrome on 
subsequent cardiac outcomes. We applied the five year experience of the West of Scot- 
land Coronary Prevention Study (WOSCOPS) to directly quantify the prognostic impact 
of METS. Methods: The study population comprised 6,447 males enrolled in the 
WOSCOPS trial aged 45-64 years, with LDL-C 156-255 mg/dl. Diabetics and subjects 
with fasting glucose x= 126 mgldl were excluded. We defined the presence of METS as 
any three of the following: Body Mass Index >30 kglm2, HDL-C less than 40 mgidl, trig- 
lycerides > 150 mgldl, fasting glucose >= 110 - 125 mgidl. and systolic blood pressure 
>=I30 mmHg or diastolic >= 85 mmHg or treated for hypeltension. Cardiac events were 
defined as fatal or non-fatal CHD, or revascularization (CABG or PTCA). Cox regression 
was used to estimate the independent contribution of METS to events, with age, LDL-C, 
current smoking, and pravastatin treatment as covariates. Results: The overall preva- 
lence of the metabolic syndrome was 23.8%. Cardiac event rates were 12.6% and 7.3% 
for subjects with and without METS respectively (pc.0001). The hazard ratio describing 
the association of METS with events was 1.8 (95%CI: 1.5-2.1, pc.OOOl), which was com- 
parable to age(per 10 years): 1.8(95%CI:1.5-Z.O,p<.OOOl), and greater than smoking: 1.5 
95%CI:1.3-1.8). and LDL-C: 1.4 (95%CI:l .1-i .6,p<.OOl). Conclusions: This study is the 
first reported quantification of the independent association of METS with CHD in a longi- 
tudinal cohort of males. The prognostic impact of METS is similar lo other traditional risk 
factors such as LDL-C, age. and smoking. Therapies which target METS risk factors in 
combination should confer clinical benefit lo METS patients. 
11:15a.m. 
845-4 Differential Effects of Statins on Hypercholesterolemic 
Patients With Metabolic Syndrome 
Donald 8. Hunninahake, Christie M. Ballantyne, Darbie L. Maccubbin, Awind K. Shah, 
Barry Gumbiner, Yale B. Mitchel. Heart Disease Prevention Clinic, Minneapolis, MN, 
Merck Research Laboratories, Rahway, NJ 
Background: Hypercholesterolemic (HC) patients with metabolic syndrome (MS) are at 
high risk for coronary heart disease (CHD) due to elevated LDL-C and triglycerides (TG), 
and low HDL-C, all independent predictors of CHD. We compared the lipid-modifying effi- 
cacy of simvastatin (S) and atolvastatin (A) in HC patients with MS. 
Methods: This post-hoc analysis was performed on data from a 36-week, multicenter, 
double-blind dose titration study designed to evaluate the effects of S (40-80 mg) and A 
(20-80 mg) on HDL-C in HC patients (LDL-C >I60 mg/dL). Per NCEP ATPIII, patients 
ware classified as having MS if they met 3 or more of the following criteria: TG 2150 mg/ 
dL; HDL-C ~40 (men) or ~50 (women) mg/dL; type 2 diabetes and/or fasting serum glu- 
cose 21 IO mg/dL; hypertension and/or blood pressure Ll3Ok85 mmHg; and body mass 
index 230 (surrogate for waist circumference). 
Results: Of 808 evaluable patients, 212 (26%) had MS at baseline. with 99 and 113 in 
the S and A groups, respectively. At comparable LDL-C- and non-HDL-C-lowerlng 
doses, both drugs produced large reductions in TG with A producing greater decreases 
in 2 of 3 dose comparisons. In contrast, the increases in HDL-C with S were -1.5 to 3- 
fold those observed with A af every dose (table). After 36 weeks, -50% of the MS 
patients in both treatment groups converted to non-MS status. 
Conclusion: Both simvastatin and atorvastatin effectively modified LDL-C, TG and non- 
HDL-C in HC patients with MS; however, simvastatin provided greater increases in HDL- 
C. 
LDL-C 
% change 
(95% Cl) 
HDL-C 
% change 
(95% Cl) 
TG 
% change 
(95% Cl) 
Non-HDL-C 
% change 
(95% Cl) 
845-5 
!%I(Wk6 AZO(Wk6 SBO(Wk1 A40(Wkl Sso(Wkl8 A8O(Wkl8/ 
) 1 2) 2) /36) 36) 
-42 (-44, - -46 (-47, - -49 (-51, - -50 (-52, - -49 (-51, - -50 (-53, - 
@J) 44) 48) 48) 46) 47) 
10 (8, 12) 6 (4, 8) IO (7, 12) 5 (2.7) 9(7.11) 3U.5) 
-30 (-34, - -24 (-29, - -27 (-32, -34 (-38, -27 (-31, -32 (-36, 
26) 1% 23) 29) 23) 28) 
-39 (-42, -42 (-43, -45 (-47, -46 (-48, -45 (-47, -47 (-50, - 
37) 40) 43) 44) 42) 44) 
11:30 a.m. 
Elevated C-Reactive Protein in High-Risk Asymptomatic 
Individuals Is Strongly Associated With the Metabolic 
Syndrome 
Samia Mora, Roger S. Blumenthal, Lisa R. Yanek, Taryn F. Moy, Lewis C. Becker, Diane 
M. Becker, Johns Hopkins Medical Institutions, Baltimore. MD 
Background: Chronic inflammation has been associated with certain components of the 
metabolic syndrome (MS), including increased body mass index and serum lipids, but it 
is unclear if inflammation should be considered part of the syndrome. 
Methods: We investigated whether high-sensitivity C-reactive protein (hs-CRP) is inde- 
pendently associated with the clustering of metabolic abnormalities in 388 apparently 
healthy siblings (SIBS) of individuals with premature coronary heart disease (mean age 
of SIBS 52 * 8 years, 43% male, 60% African-American). MS components were defined 
using ATP Ill guidelines for abdominal obesity. high triglycerides, low HDL cholesterol. 
high blood pressure, and high glucose. 
Results: Mean hs-CRP was 4.4 f 3.5 mg/L. There was a significant difference in mean 
hs-CRP in those with MS (z 3 components) compared to those without MS (5.7 versus 
4.0, p<O.OOOl). There was a graded increase in mean hs-CRP levels with increasing 
number of MS components present, p for trend <O.OOOl (Table). Using multiple linear 
regression, each additional component of MS was associated with a 0.9 * 0.1 mg/L 
increase in mean hs-CRP level (p<O.OOOl), after adjusting for age, sex. race. and smok- 
ing status. 
Conclusion: These findings suggest that chronic inflammation is strongly associated 
with the metabolic syndrome in high-risk individuals who may benefit from funher risk- 
stratification using hs-CRP levels. 
MS Components (No.) 0 1 2 3 4 5 
Mean hs-CRP (mglL) 2.2 3.9 4.9 5.4 6.2 6.1 
N 61 98 120 66 31 12 
11:45 a.m. 
845-6 The Association of the Metabolic Syndrome With 
Myocardial Infarction and Stroke in the National Health 
and Nutrition Examination Survey Ill 
John K. Ninomiva, Gilbert J. L’italien, Michael H. Criqui, Joanna L. Whyte. Anthony 
Gamst, Roland S. Chen, University of California, San Diego, School of Medicine 
Epidemiology, San Diego, CA, Bristol-Myers Squibb, PRI, Princeton, NJ 
Background: The association of the Metabolic Syndrome and its component conditions 
with self-reported history of myocardial infarction (Ml) and stroke was evaluated in a 
large cross-sectional population suway. the NHANES Ill, 1988-1994. Methods: Based on 
NCEP Adult Treatment Panel Ill (NCEP-ATP Ill) criteria. we evaluated 10,357 subjects 
for each of the five component conditions of the Metabolic Syndrome: insulin resistance 
(IR). abdominal obesity based on waist circumference (WC), hypertriglyceridemia. low 
HDL-cholesterol, and hypertension (HTN), and the overall syndrome defined as 3 or 
more of the 5 conditions. Logistic regression was used to estimate the association of the 
svndrome. and each of its 5 component conditions individuallv. with Ml and stroke. Mod- 
els were adjusted for age. sex, race and smoking history. SUDAAN software was used to 
weiaht for the complex samolina frame used in NHANES Ill. Results: The prevalence of 
I  
Ml was 3.7%, stroke 2.0% and the combined outcome (either or both) 5.2%. The Meta- 
bolic Syndrome was significantly related in multivariate analysis to Ml (OR = 2.01, 95% 
Cl = 1.53 - 2.84), stroke (OR = 2.16, 95% Cl = 1.48 - 3.16) and the combined outcome 
(OR = 2.05, 95% Cl = 1.64 - 2.57). The combined outcome association was observed in 
both women (OR = 2.20, 95% Cl = 1.56 - 3.11) and men (OR = 1.98, 95% Cl = 1.34 - 
2.78). Among the component conditions, IR (OR = 1.30, 95% Cl = 1.03 - 1.66), low HDL 
(OR = 1.35,95% Cl = 1.05 1.74), HTN (OR = 1.44,95% Cl = 1 .OO, 2.08) and hypertng- 
lycendemia (OR = 1.68, 95% Cl = 1.20 - 2.30) were significantly related to the combined 
outcome in multIvariate analysis; only obesity, as measured by waist circumference, was 
not independently related to disease (OR. = 1 .I 1, 95% Cl = 0.88 - 1.42). Conclusions: 
These results indicate a strong, consistent relationship of the Metabolic Syndrome, as 
defined in NCEP-ATP Ill, with history of MI and stroke. The individual component condi- 
bow. IR, HTN. low HDL and hypertriglycerldemia were all found to be significantly asso- 
ciated with histoly of Ml and stroke. These results emphasize the impoltance of the 
Metabolic Syndrome in the progression of atherosclerotic disease. 
847 
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847-l Lipocalin-Type Prostaglandin D Synthase as a Sensitive 
Biomarker for Coronary Atherosclerosis 
Yoii Kate, Yoshiyuki Kijima. Yasuhiko Mats”-ura, Takenori Yasuda, Yutaka Eguchi. 
Teruo Inoue, Hiroshi Oda, Kousuke Seiki, Nanae Taniguchi, Kousuke Aritake, Haruko 
Kumanogoh. Naomi Eguchi, Yoshihiro Urade, lshinkai Yao General Hospital, Yao, 
Japan, Osaka Bioscience Institute, Suita, Japan 
Background: Lipoprotein(a). C-reactive protein (CRP), and lipocalin-type prostaglandin D 
synthase (L-PGDS) have been proposed as serum markers for coronary artery disease, 
but no consensus has yet been reached. 
Methods: Serum levels of L-PGDS. lipoprotein(a). and CRP were measured I” samples 
taken from the ascending aorta and great cardiac vein in 38 patients with chest symp- 
toms who were investigated by coronary anglography. lmmunohistochemical localization 
and mRNA expression for L-PGDS were determined in autopsy specimens. 
Results: The aortic and venous levels of L-PGDS and the veno-aortic difference were 
increased in patients with single (meaw57.1, 65.2, and 8.1 pgldl, respectively) and mul- 
tiple (69.1, 82.0, and 13.0 wg/dl, respectively) vessel disease compared wth those in the 
patients with normal coronary angiography or coronary risk factors (48.5, 51.6 and 3.1 
pg/dl, respectively). The aoltic and venous levels in patients with multiple vessel disease 
were significantly (p=O.O009-0.046) higher than those of the other 2 groups. The veno- 
aortic differences were significantly higher in patlen& with multiple vessel disease than in 
those with normal coronary anglography (p=O.Ol). However, neither lipoprotein(a) nor 
